Skip to main content
. Author manuscript; available in PMC: 2023 Jun 5.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2185–2191. doi: 10.1158/1055-9965.EPI-22-0548

Table 1.

Demographics

Cervix (N=250) Vagina (N=28) Vulva (N=46) Total (N=324) P-value

Diagnosis, n (%)
  Pre-invasive disease1 229 (92%) 28 (100%) 41 (89%) 298 (92%)
  Cancer 21 (8%) 0 (0%) 5 (11%) 26 (8%)
Study Center, n (%) <0.0012
 MD Anderson Cancer Center 112 (45%) 24 (86%) 42 (91%) 178 (55%)
 LBJ Hospital 138 (55%) 4 (14%) 4 (9%) 146 (45%)
Age <0.0013
 Median (IQR) 41 (34, 52) 56.5 (48, 61.5) 60.5 (51, 65) 45 (36, 57)
Race, n (%) 0.8662
 Asian 6 (2%) 0 (0%) 0 (0%) 6 (2%)
 Black or African American 27 (11%) 3 (11%) 7 (15%) 37 (11%)
 White 205 (82%) 24 (86%) 39 (85%) 268 (83%)
 American Indian / Alaska Native 1 (0%) 0 (0%) 0 (0%) 1 (0%)
 Subject declined to answer 1 (0%) 0 (0%) 0 (0%) 1 (0%)
 Unknown 10 (4%) 1 (4%) 0 (0%) 11 (3%)
Ethnicity, n (%) <0.0012
 Hispanic or Latina 142 (57%) 4 (14%) 4 (9%) 150 (46%)
 Not Hispanic or Latina 107 (43%) 24 (86%) 42 (91%) 173 (54%)
 Missing 1 0 0 1
Menopausal Status, n (%) <0.0012
 Pre-Menopausal 171 (74%) 6 (21%) 12 (27%) 189 (62%)
 Post-Menopausal 60 (26%) 22 (79%) 32 (73%) 114 (38%)
 Missing 19 0 2 21
HIV Status, n (%) 0.3202
 Negative 231 (99%) 26 (96%) 41 (98%) 298 (98%)
 Positive 3 (1%) 1 (4%) 1 (2%) 5 (2%)
 Unknown 16 1 4 21
Previous HPV vaccine? n (%) 0.6252
 No 175 (71%) 22 (81%) 37 (80%) 234 (73%)
 Yes 5 (2%) 0 (0%) 0 (0%) 5 (2%)
 Unknown 67 (27%) 5 (19%) 9 (20%) 81 (25%)
 Missing 3 1 0 4
1

Diagnoses included for pre-invasive disease: cervix = CIN 2/CIN 3/HSIL/AIS, vagina = VAIN 2/VAIN 3/HSIL, vulva = VIN 2/VIN 3

2

Fisher Exact p-value

3

Kruskal-Wallis p-value;

Two patients had cervical diagnosis CIN 2/CIN 3 and vaginal diagnosis VAIN2/VAIN3. They are included in the Cervix group.